Table of Contents

Agenda………………………………………………………………Page 2

President Message…………………………………………………..Page 3

Keynote Speech

Dr. David Anton…………………………………………………. Page 4

CleanTech through Biotech

Dr. Arjun Natesan………………………………………………....Page 5

Human Embyonic Stem Cell: Route to Therapeutic Applications

Ms. Wei Huang…………………………………………………....Page 6

Bio Fuel: Bioprocess Dr. Johnson TY Lau……………………………………………... Page 7 Biotechnology Development in Asia: opportunities and Challenges

Panel Discussion

Dr. Jing-Shan Hu………………………………………………..Page 8

Dr. Larry Hsu……………………………………………………Page 9

Dr. Marietta Wu…………………………………………………Page 10

Ms. Lee Sar Tan………………………………………………...Page 11

Dinner Speaker

Prof. Ginger Cheng-Chi Hsü…………………………………….Page 12

1

Agenda

12:00 – 1:00 Registration

1:00 – 1:15 Welcome & Opening Remarks

Ms. Stella Chang, CBA President Dr. Sydney Chen, Program Chairperson

1:15 – 1:55 CleanTech Through Biotech

Dr. David Anton Senior Vice President, R&D, Codexis Inc. Moderator: Dr. Katy Korsmeyer

1:55 – 2:35 Human Embryonic Stem Cells: Route to Therapeutic Applications

Dr. Arjun Natesan Group Leader Cell Technology, Geron Corporation

Moderator: Dr. Albert Chueh

2:35 – 3:15 Bio Fuel: Bioprocessing

Ms. Wei Huang Vice President, LS9 Inc.

Moderator: Mr. Cesar Ho

3:15 – 3:30 Coffee Break

3:30 – 4:10 Biotechnology Development in Asia - Opportunities and Challenges 2009

Dr. Johnson YN Lau Executive Chairman, XenoBiotic Laboratories & Kinex Pharmaceuticals

Moderator: Dr. Kelley Liu

4:10 – 5:40 Panel Discussions

Bridging US-Asia Biopharmaceutical Industry: Opportunities and Challenges Chairperson: Dr. Jing-Shan Hu, Director Licensing & External Research, Merck & Co Dr. Larry Hsu, President, CEO & Director, Impax Laboratories Dr. Marietta Wu, General Manager Greater China, Burrill & Company Dr. Johnson YN Lau, Executive Chairman, XenoBiotic & Kinex Ms. Lee Star Tan, Director, Contact Singapore

5:40 – 5:50 Closing Remarks

Dr. Sydney Chen, Program Chairperson

5:50 – 6:30 Networking Mixer

6:30 – 9:00 Dinner

Keynote Speaker: Professor Ginger Cheng-chi Hsu, UC-Riverside

Speaking of Chinese Painting – Notes on Gender, Literature and Consumption “茶餘飯後談畫”

2

Introduction from the president of CBA

The Chinese Bioscience Association has been established for more than 10 years in the Bay Area. Our mission is to facilitate professional interactions and net working. We are proud that during this period, CBA has held hundreds of events; helped many scientists, post-docs,and students to find jobs or change career directions. Our accomplishments have brought us an increase in membership each year. Our enthusiastic board members and experienced advisors made CBA a well known organization.

This year CBA has already organized free seminars on

patent law; Career networking, Building a Start-Up: How to transform from a scientist to a corporate manager; How to make networking FUN; Personalized Medicine: Its Promises and Challenges. We also kicked off the BioEntrepreneur Club, serving as a bridge between technology and business people, and began our new Mentorship Program for young scientists. We are also planning for Asia Trip: To understand investment environment and policies in Asia, to explore new business opportunities, and to find partners in Asia. The theme of this year’s conference is “Emerging Trends in Bioscience Industry”, with scientific experts and business development leaders presenting the latest information on emerging biotechnological development and business opportunities around the world. The attendees of the conference range from local scientists and entrepreneurs, to government agents, company executives, investors and even the general public. I would like to thank those of you who supported our successful past conferences, and assure you that this year we will strive to make it even better. As always, your support and participation has been the key driver of CBA’s path, and I know that you, the members, sponsors and friends will continue that support and participation to our growth and progress. Your involvement, your energy, and your commitment have known no ends. I appreciate it, and I know CBA is now and will continue to be better for it going forward. Best regards, Stella Chang President, CBA 2009

3

Bioscience: New Technology and Industry Outlook

Dr. Dave Anton, Senior. V. P. in Research and Development, Codexis

Dr. Anton was named Senior Vice President,

Research and Development in 2009. He joined Codexis in 2008 as Vice President, Research and Development, for Codexis Bioindustrials. He is responsible for directing research and development across the company. Dr. Anton has over 25 years experience directing development of new technology solutions and production processes. He joined DuPont in 1983, and held a variety of senior research management positions across bioprocessing and biocatalysis. He led the process research, development and commercialization of several

products, including 1,3 propanediol (a chemical intermediate used in a variety of industrial applications ranging from airplane deicing fluids to textiles and carpet). As Vice President, Research and Development for DuPont’s joint venture with Tate and Lyle, he directed technology start-up activities for the first 100 million-pound plant for 1,3 propanediol, commissioned in Loudon, TN in 2006. As Venture Manager, Biofuels, he was global business lead for development of DuPont’s advanced biofuel, biobutanol. He holds a bachelor’s degree in biochemistry from the University of California, Berkeley, and a Ph.D. in biochemistry from the University of Minnesota. He is a member of the joint DOE/USDA Biomass Research and Development Technology Advisory Committee. Codexis is a leading developer of biocatalytic chemical processes that can dramatically reduce manufacturing costs across a broad range of industries. Our proprietary technology enables novel solutions for cost-effective, efficient and environmentally sound production of pharmaceuticals, transportation fuels, and industrial chemicals. Our focus is on improving R&D productivity for our partners while significantly reducing their capital expenditures and cost-of-goods using green chemistry methods.

Human Embryonic Stem Cells: Route to Therapeutic Applications

4

Dr. Arjun Natesan, Group Leader of Cell Technologies, Geron Corp.

Dr. Arjun Natesan joined Geron Corporation’s Regenerative Medicine Department in 2005. He is currently Group Leader for Cell Technologies in the stem cell biology program, responsible for research on the composition and function of human embryonic stem cell derived products. His work includes early-stage assay identification which enables research-stage products to efficiently transition to clinical use. Prior to Geron, Dr. Natesan was a post-doctoral fellow at the National Institute of Mental Health, with a focus on fundamental rhythmic properties of the retina and brain. He has published several peer-reviewed papers and presented at key

industry conferences on stem cell derived products. Dr. Natesan received his Ph.D. in neuroscience from Texas A&M University in 2001. Abstract Human Embryonic Stem Cells (hESCs) can be propagated indefinitely yet still be differentiated to form all major lineages of somatic cells in the body. Protocols have been developed to differentiate at least 8 specific cell types from hESCs including oligodendrocyte progenitor cells, cardiomyocytes, hepatocytes, neural progenitors, dopaminergic neurons, osteoblasts, and endothelial cells. Detailed phenotypic and in vitro functional studies have shown that these cells resemble their normal counterparts in human tissue. Further, several investigations have been performed showing that differentiated hESC populations survive, engraft, and function in animal models of human disease. Several challenges have to be met to move a stem cell product to the clinic. On the research side, it is necessary to develop a reproducible, refined, scalable method for the differentiation of hESCs to a target cell type. Secondly, these cells must be shown to both safe and efficacious in appropriate animal models. From a development perspective, methods for large-scale production of hESCs must be developed to produce sufficient starting material for the production of the therapeutic cell type. Reliable and quantifiable methods must be developed to characterize the composition and function of the cell product. Significant progress has been made in each of these areas, and this will be discussed with specific examples from the development of hESC-derived oligodendrocyte progenitor cells, cardiomyocytes, and pancreatic β-cells that are currently being produced at Geron.

5

Bio Fuel: Bioprocessing

Dr. Wei Huang, VP of Process Development and Engeering, LS9

Wei Huang is the VP of Process Development and Engineering at LS9; where she is responsible for process development, scale up and engineering effort. She has nearly 20yr of experience in process development, scale up and product commercialization for the biotechnology industries. Prior to LS9, Wei was a director at Fluor Corporation; where she has led multi-million dollar engineering projects around the world. Wei is a director at AIChE NorCal Chapter, committee member of ASME BPE. She is also an active member of AIChE, ACS, AOCS, and ISPE.

Abstract

The urgent need for renewable alternatives to petroleum has fueled global efforts to commercialize technologies for the conversion of abundant renewable biomass to liquid transportation fuels. In addition to chemical and thermochemical conversion approaches, biocatalytic conversion technologies are being aggressively developed. At LS9, we apply the basic principles of synthetic biology to engineer microbes to efficiently convert renewable carbohydrates directly to diesel and other petroleum derived products. LS9, Inc. has developed a core technology to convert fermentable sugar to high quality, low cost drop in replacement fuels and chemicals. LS9 leverages the energetically efficient fatty acid biosynthetic pathway in combination with an engineering strategy that places all chemical conversions in a single whole cell catalyst. These Microrefinery™ catalysts enable a specific and efficient route to a high performing diesel substitute that is competitive with existing oil prices without subsidy. This talk shall discuss the fundamental technology, fermentation and downstream process, fuel performance, the underlying economics, GREET analysis, a contrast with alternative routes and technologies, and a development plan to commercial launch.

6

Biotechnology Development in Asian: Opportunities and Challenges

Dr. Johnson YN Lau, Executive Chairman, XenoBiotic Laboratory & Kinex Pharmaceuticals

Dr. Lau has a varied background including academic medicine, financial management and executive management of pharmaceutical/biotech companies. Dr. Lau is currently Executive Chairman of XenoBiotic Laboratories. Dr. Lau also serves as Executive Chairman of Kinex Pharmaceuticals. Dr. Lau also serves as Vice-Chairman of Tanvex Biologics Corporation, Taivex Therapeutics Inc, as well as Board members of Chelsea Therapeutics and Morria Pharmaceuticals and Advisors to other Pharmaceutical companies. Dr. Lau was previously Managing Director of Healthcare Investment Banking of Roth Capital Partners. Before that he was Chairman and CEO of Ribapharm Inc. where he led the second largest IPO in the 20 years of biotechnology history. Prior to that

he was Senior VP and Head of R&D at ICN Pharmaceuticals, was Senior Director of Antiviral Therapy at Schering-Plough and was a member of the faculty of Gastroenterology, Hepatology, and Nutrition as well as Molecular Genetics and Microbiology at the University of Florida. Dr. Lau has been involved with a number of successful Investigational New Drugs (INDs) and New Drug Applications (NDAs). He has published over 200 scientific papers, over 60 chapters, reviews and editorials in leading scientific journals, edited two books and has more than 10 patents. He is a Fellow of the Royal College of Physicians of the United Kingdom and received his medical degree and doctoral degree from the University of Hong Kong. Abstract Dr. Lau's talk will cover overview of biotech and pharma businesses in Asia, highlighting China's presence in this sector. He will discuss that how the successes in drug discovery and development often rely on innovation and coordination, as biotechnology is cross-displinary in nature. The ability to maintain the synergy and channel the multiple discipline approches into a coordinated effort shall be the key.

7

Bridging US-ASIA Biopharmaceutical Industry

Dr.Jing-Shan Hu 胡靜珊博士, Director, Licensing & External Research, Merck & Co

Dr. Jing-Shan Hu is currently Director of Licensing & External Research (Mainland China, Hong Kong, & Taiwan) at Merck & Co., Inc., USA. She is responsible for identifying and developing opportunities related to partnership, licensing-in, and acquisition for new drug candidates and technologies for drug discovery and development in Mainland China, Hong Kong, and Taiwan. Prior to joining Merck & Co., Inc., Dr. Hu spent over three years with Roche Pharmaceuticals at Palo Alto as Research Leader and Head of Functional Biology following serving as the Program Leader for Toxicogenomics. Prior to that, she worked at Affymetrix in various capacities,

including as Program Manager of Toxicology/Pharmacogenomics, establishing and managing programs with both pharmaceutical and academic partners to develop and demonstrate the application of Affymetrix GeneChip technology. She started her career at Human Genome Sciences as one of the founding scientists and Project Leader of VEGF-2 Protein Therapeutics program. Dr. Hu got her B.S. degree in Biochemistry from Peking University; Ph.D. from Univ. of Texas & M.D. Anderson Cancer Center through CUSBEA program; her post-doctoral training at Harvard Medical School. She has authored 15 papers in peer reviewed journals such as Science, Nature Genetics, and Nature. She is also an inventor of 16 patents and patent applications. She has served as the 2006-2007 President of Sino-American Pharmaceutical Professionals Association – West (SAPA-West) and the 2002-2003 Chairperson of the Board of Peking University Alumni Association of Northern California (PKUAANC). Dr. Hu has 16 years of research, management, & business development experience in biotech and pharmaceutical industry in the US. Abstract As multi-national companies (MNC) in healthcare industry are facing more challenges than ever to create innovative drugs and vaccines due to low probability of success and patent expiration, etc., partnership and R&D externalization becomes more and more important for innovation, increasing probability of success, cost reduction, etc. Via the vision and efforts from late 90's, Merck Sharp & Dohme/MSD (Merck & Co, Inc, Whitehouse Station, NJ, USA) has developed a systemic approach and strategy to form partnership with various organizations to create values and share successes together. We also have new initiatives to strengthen further our external R&D outcome and commercialize on follow-on biologics (FOB). These will create new opportunities for both sides of the Taiwan Strait to partner with us and build world-class biotech and pharmaceutical industry in both service and innovative arenas. I will discuss these opportunities in more details in this presentation.

8

Impax Laboratories and Its Taiwan-Based Globalization Strategy

Dr. Larry Hsu 許中強博士, President & CEO, Impax Laboratories, Inc. Dr. Hsu co-founded Impax Pharmaceuticals, Inc.

with Dr. Charlie Hsiao in early 1995. Impax is a drug-delivery technology-based pharmaceutical company located at San Francisco Bay Area. In December 1999, Impax Pharmaceutical, Inc. went public through a reverse acquisition of Global Pharmaceuticals and changed its name to Impax Laboratories, Inc. Dr. Hsu was the President of Impax Laboratories until October 2006 when he assumed additional responsibility of Chief Executive Officer. Dr. Hsu received his Ph.D. degree in Pharmaceutics from University of Michigan. He worked at Abbott laboratories for 15 years. During the last four years at Abbott, Dr. Hsu Development in charge of worldwide product development,

process engineering, clinical supplies manufacturing and production technical support of all dosage forms. Dr. Hsu received his B.S. degree in Pharmacy from National Taiwan University.

was the Director of Product

Abstract Impax Laboratories, Inc., a U.S. NASDAQ-listed company (www.impaxlabs.com), was co-founded by Drs. Larry Hsu and Charlie Hsiao in 1995. It is a technology-based specialty pharmaceutical company applying its drug delivery technology and clinical development expertise to the development, manufacturing and distribution of controlled-release and specialty generics and branded prescription drugs. Impax Laboratories currently has more than 40 generic products on the U.S. market with additional 28 ANDAs pending at FDA for approval and 43 generic products under development. Most of these products are controlled-release or difficult-to-formulate products. Impax Laboratories also has two brand product candidates in phase III clinical trials targeting Parkinson’s Disease and Multiple Sclerosis patients. The NDA filings of these two products are scheduled in 2011 and 2012, respectively.In late 2006, Impax made decision to initiate effort in globalization of its business by establishing a wholly owned subsidiary in Taiwan and commenced the construction of an R&D and manufacturing facility in 4Q2007. Impax Laboratories (Taiwan) is located in Jhunan Science Park, Taiwan. The USD$25 million and 100,000ft2 newly constructed R&D and manufacturing facility at Jhunan Science Park is designed to meet U.S. FDA, European EMEA and Taiwan DOH cGMP requirements. It has state-of-art equipment capable of producing oral solid dosage form products (tablets, capsules and granules) ranging from several thousand units per batch to more than one million units per batch. This facility recently passed its first U.S. FDA inspection. The routine commercial operation is scheduled to begin in early 2010. All initial production will be for the U.S. market. Impax (Taiwan) will serve as a strategic R&D and commercial manufacturing center for Impax’ U.S. and global pharmaceutical markets.

9

Bridging US-Asia Biopharmaceutical Industry: Opportunities and Challenges

Dr. Marietta Wu, General Manager Greater China, Burrill & Company

Dr. Wu’s experience ranges from clinical medicine and medical research to finance and entrepreneurship. In her currently role at Burrill & Company, she focuses on venture capital investing in China and Taiwan related life sciences opportunities and manages the fund raising effort for the Burrill Asia Fund. In addition, she also helps US and Chinese life sciences companies form partnerships. Dr. Wu is a frequent speaker and author on Greater China life sciences topics. Prior to joining Burrill, Dr. Wu held professional positions with Edwards Lifesciences and Eli Lilly & Company. She was Director of Strategy at Edwards, responsible for the

strategic planning in the biologics program. At Eli Lilly & Company Oncology and Integrated Biology, Dr. Wu oversaw finance, business development, pipeline valuation, organizational restructure and outsourcing strategy. She also worked at Eli Lilly’s M&A Group and with Oncology Discovery Research. Dr. Wu founded BioHorizon, a consultancy focused on value creation in the life sciences industry across the Pacific Rim. She advised a number of biotech start-ups and venture capital firms. Dr. Wu also has leadership positions in several professional organizations promoting cross-Pacific business initiatives including serving as secretary general for the BayHelix Group. Dr. Wu’s scientific expertise centers on basic and clinical research in oncology and neuroscience. She was selected by Nobel Laureate Dr. Marshall Nirenberg as an IRTA Fellow at the National Institutes of Health (NIH). Dr. Wu received her M.D. from Shanghai Second Medical University, a Ph.D. in Medical Sciences with a focus in biochemistry and molecular biology from Medical College of Ohio, and an MBA from the University of Michigan Business School.

10

Bridging Biopharmaceutical Industry between Asia-Pacific and US 

 Ms. Lee Sar Tan, Director, Contact Singapore

Ms Lee Sar Tan is the Area Director for Contact Singapore based in Northern California. Contact Singapore is a non-profit organization that provides information on career, relocation and business opportunities in Singapore. Prior to her current stint, Lee-Sar was a Human Resource professional in the area of recruitment and talent attraction. She has also worked in a business development role with the Singapore Economic Development Board, assisting global companies on their plans to establish their Asian operations there. Lee Sar holds a degree in Business Administration from the Nanyang Technological University, and a Masters in Industrial Psychology from New York University,

Contact Singapore is a non-profit agency whose primary function is to draw global talent to work, invest and live in Singapore. It is an alliance of Singapore’s Economic Development Board and Ministry of Manpower.

With offices in the Asia Pacific, Europe and North America, it is a one-stop contact point for non-Singaporeans and Overseas Singaporeans interested in working, investing and living in Singapore. Contact Singapore actively links Singapore-based employers with global talent and provides updates on career opportunities and industry developments in Singapore. It also attracts those who are keen to invest in or initiate new business activities in Singapore.

For more information on working, investing and living in Singapore, please visit www.contactsingapore.sg

Abstract

Lee Sar will provide a broad overview of Singapore’s initiatives in the Biomedical Sciences sector, highlighting the new developments in manufacturing and R&D in the pharmaceutical, biologics and medical devices sectors. She will also provide an overview of working and living in Singapore.

11

茶 餘 飯 後 講 畫 Speaking of Chinese Painting----Notes on Gender, Literature, and

Consumption

Prof. Ginger Cheng-Chi Hsü 徐 澄 琪, Department of the History of Art, UC-Riverside

Professor Ginger Hsü is a historian of later Chinese

art and culture. As a history major from the National Taiwan University, she was trained as an art historian and earned her PhD degree from the University of California, Berkeley. While currently teaching at the University of California, Riverside, she publishes primarily in the area of Chinese painting with a special interest in topics such as elite and popular culture, production and exchange of artwork, regions and networks. Her book, A Bushel of Pearls: Painting for Sale in Eighteenth-Century Yangchow (Stanford University Press, 2001) investigating the commodification of literati painting in mid-Qing China, offers a new perspective to the study of the “Eight

Eccentrics of Yangchow”. Her most recent publication “Traveling to the Frontier” that appeared in Lifestyle and Entertainment in Yangzhou (NIAS, 2009) is a study of frontier travel, commercial expansion, and political exile under the Qianlong reign.

12

Senior Advisors in CBA

Dr. Jin-Long Chen Dr. David Chien Dr. Keelung Hong Dr. Frank Kung Prof. Rong-Hwa Lin Dr. Ching H. Wang

Sponsor List Merck Teco

Jeng Her QPS CAE

ScinoPharm Abgenomics

ECG MonteJade Julia Hsiao

ITRI CIE

Allcells Primary Realty and Finance

HKSTP Wisbiomed

Hsinchu Antagene Inc

Matchbin TAITRI

13

CBA 2009 Events

For more information and events, please visit

www.cbasf.org

14